BARI CLINICAL UNITS

BARI将由一项前瞻性随机试验组成，旨在比较 经皮冠状动脉腔内成形术和冠状动脉旁路移植术治疗慢性阻塞性肺疾病的远期疗效 多支冠状动脉病变与严重心绞痛、不稳定型心绞痛或心绞痛 急性心肌梗死后，以及所有接受冠状动脉介入治疗的患者的登记 12岁时因严重或不稳定的心绞痛而进行的血管造影术，有无心肌梗死 参与临床站点。大约1800名患者将被随机分配到 PTCA或CABG在24个月的招募期间和持续时间 随诊时间至少为四年。临床和客观数据 将在登记处和随机分组中为每个受试者收集 在入院时和随访期间进行试验。治疗的最佳选择尚不清楚 目前对于这些严重冠状动脉病变的大亚群患者 疾病和随机试验应该建立相对的优点 PTCA和CABG，即每个手术的安全性和成功率， 心绞痛复发率、需要再次干预和晚期发生 冠状动脉事件，并帮助确定应该应用哪种程序 第一。在若干目标中，登记处数据将评估 将试验结论推广到更大范围人群的有效性 严重心绞痛和多支冠状动脉疾病的患者。

BARI will consist of a prospective randomized trial designed to compare the long-term efficacy of PTCA and CABG in clinical subsets of patients with multivessel coronary disease and severe angina, unstable angina or angina after acute MI, and a registry of all patients undergoing coronary angiography because of severe or unstable angina, with or without MI, at 12 participating clinical sites. Roughly 1,800 patients will be randomized to PTCA or CABG during the 24-month recruitment period and duration of follow-up will be a minimum of four years. Clinical and objective data will be collected for each subject in the registry and in the randomized trial at entry and during follow-up. The best choice of therapy is unclear at present for these large subsets of patients with severe coronary artery disease and the randomized trial should establish the relative merits of PTCA and CABG, namely the safety and rate of success of each procedure, recurrence rate of angina, need for re-intervention and occurrence of late coronary events, and help to determine which procedure should be applied first. The registry data will, among several objectives, assess the validity of extending the conclusions of the trial to a larger population of patients with severe angina and multivessel coronary disease.